Webinar Date/Time: Thursday, May 9, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Learn more about why CROs are advocating for operational shifts necessary to support the adoption of innovative solutions to capture data and the significance of partnering with a CRO who can support initiatives throughout the entire clinical trial continuum using innovative data capture methods and their knowledge to facilitate global submissions.
Register Free: https://www.pharmexec.com/pe/clinical-trial-partner
Event Overview:
Faced with an increasingly more competitive future, CROs are spearheading of adoption of modern clinical applications to increase efficiency, enhance collaboration, and improve clinical trial performance. Advances in clinical trial processes have arisen as a result of cross-company collaborations amongst CROs and various industry stakeholders – constrained by time and compelled by regulatory compliance – to support broader industry-wide adoption of innovations.
Learn more in this webinar about why CROs are advocating for operational shifts necessary to support the adoption of innovative solutions to capture data and the significance of partnering with a CRO who can support initiatives throughout the entire clinical trial continuum using innovative data capture methods and their knowledge to facilitate global submissions.
Key Learning Objectives
Who Should Attend
Full Agenda
Thursday, May 9th:
10:00 am EDT Driving Your Organizations Success and Transformational Initiatives in Clinical Trials
Ryan Kennedy, Global VP, Product Strategy, Experience, and Enablement; Oracle
Sean Roy, Senior Consulting Practice Director; Oracle
Drew Zwiebel, Global Vice President, Alliances & Channels; Oracle
Raj Modi, Senior Director, Global Customer Centre of Excellence; Oracle
11:00 am EDT The Conundrum of Proliferating Data from Decentralized Clinical Trials
David Blackman, Executive Director Digital Trials Strategy; Oracle, and other non-Oracle speakers.
12:00 pm EDT How CROs Are Leveraging Innovation to Accelerate Clinical Trials
Non-Oracle speakers
1:00 pm EDT How EU 536/2014 Will Revolutionize Global Clinical Trials
Elvin Thalund, Director, Industry Strategy; Oracle, and other non-Oracle speakers
Speakers:
Ryan Kennedy
Global VP, Product Strategy, Experience, and Enablement
Oracle
Sean Roy
Senior Consulting Practice Director
Oracle
Drew Zwiebel
Global Vice President, Alliances & Channels
Oracle
Raj Modi
enior Director, Global Customer Centre of Excellence
Oracle
David Blackman
Executive Director Digital Trials Strategy
Oracle
Elvin Thalund
Director, Industry Strategy
Oracle
Register Free: https://www.pharmexec.com/pe/clinical-trial-partner
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.